Formosa Pharma ships APP13007 ophthalmic drug to US [Yahoo! Finance]
Eyenovia, Inc. (EYEN)
Last eyenovia, inc. earnings: 3/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=254685&p=irol-irhome
Company Research
Source: Yahoo! Finance
The drug, developed using Formosa's APNT nanotechnology platform, is the first US Food and Drug Administration (FDA)-approved ophthalmic solution featuring the super-potent corticosteroid clobetasol propionate. Bora Pharmaceuticals Ophthalmic has manufactured the shipment of APP13007, which offers a twice-daily dosing regimen that is more convenient than the four doses per day required by other treatments. Eyenovia, Formosa Pharma's US partner, initiated pre-launch activities and is expected to begin the commercialisation of APP13007 by late September 2024. In 2023, Eyenovia acquired exclusive licensing and commercialisation rights for APP13007 in the US from Formosa Pharmaceuticals in an $86m deal. In August 2024, Formosa obtained a drug export licence from Taiwan's Food and Drug Administration. The licence has enabled the company to co-ordinate its first shipment to the US, a key step in its strategy for global commercialisation. In anticipation of demand within the US
Show less
Read more
Impact Snapshot
Event Time:
EYEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYEN alerts
High impacting Eyenovia, Inc. news events
Weekly update
A roundup of the hottest topics
EYEN
News
- Eyenovia Stock Tumbles on Termination of Phase III Myopia Study [Yahoo! Finance]Yahoo! Finance
- Eyenovia, Inc. (NASDAQ: EYEN) had its "neutral" rating re-affirmed by analysts at LADENBURG THALM/SH SH.MarketBeat
- Eyenovia, Inc. (NASDAQ: EYEN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $12.00.MarketBeat
- Eyenovia stock plummets following Phase III myopia trial failure [Yahoo! Finance]Yahoo! Finance
- Eyenovia, Inc. (NASDAQ: EYEN) had its "hold" rating re-affirmed by analysts at Brookline Capital Management.MarketBeat
EYEN
Earnings
- 11/12/24 - Beat
EYEN
Sec Filings
- 11/20/24 - Form 8-K
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- EYEN's page on the SEC website